92
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Immunoadsorption for heart failure is associated with normalization of iron metabolism

ORCID Icon, , &
Pages 395-400 | Received 23 Nov 2020, Accepted 06 Mar 2021, Published online: 06 May 2021

References

  • Anderson, G.J. and Frazer, D.M., 2017. Current understanding of iron homeostasis. The American journal of clinical nutrition, 106 (Suppl. 6), 1559S–1566S.
  • Andrews, N.C., 2012. Closing the iron gate. The new England journal of medicine, 366 (4), 376–377.
  • Anker, S.D., et al., 2009. Ferric carboxymaltose in patients with heart failure and iron deficiency. The new England journal of medicine, 361 (25), 2436–2448.
  • Boero, M., et al., 2015. A comparative study of myocardial molecular phenotypes of two tfr2β null mice: role in ischemia/reperfusion. BioFactors (Oxford, England), 41 (5), 360–371.
  • Bunn, H.F. and Aster, J.C., 2011. Pathophysiology of blood disorders. New York: McGraw-Hill Medical.
  • Chuang, T.-Y., et al., 2020. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. Annals of hematology, 99 (10), 2289–2294.
  • Cohen-Solal, A., et al., 2014. Iron deficiency: an emerging therapeutic target in heart failure. Heart (British cardiac society), 100 (18), 1414–1420.
  • De Domenico, I., et al., 2010. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. The journal of clinical investigation, 120 (7), 2395–2405.
  • Dong, F., et al., 2005. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clinical science (London, England: 1979), 109 (3), 277–286.
  • Fabio, G., et al., 2007. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood, 109 (1), 362–364.
  • Gujja, P., et al., 2010. Iron overload cardiomyopathy: better understanding of an increasing disorder. Journal of the American college of cardiology, 56 (13), 1001–1012.
  • Jankowska, E.A., et al., 2012. Iron status in patients with chronic heart failure. European heart journal, 34 (11), 827–834.
  • Kanamori, Y., et al., 2017. Interleukin-1β (IL-1β) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein δ (C/EBPδ) expression in hepatocytes. The journal of biological chemistry, 292 (24), 10275–10287.
  • Markousis‐Mavrogenis, G., et al., 2019. The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study. European journal of heart failure, 21 (8), 965–973.
  • Nemeth, E., et al., 2003. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, 101 (7), 2461–2463.
  • Peyssonnaux, C., Nizet, V., and Johnson, R.S., 2008. Role of the hypoxia inducible factors HIF in iron metabolism. Cell cycle (Georgetown, Tex.), 7 (1), 28–32.
  • Ponikowski, P., et al., 2015. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European heart journal, 36 (11), 657–668.
  • Rhee, J.-W., et al., 2020. Modeling secondary iron overload cardiomyopathy with human induced pluripotent stem cell-derived cardiomyocytes. Cell reports, 32 (2), 107886.
  • Roy, C.N. and Andrews, N.C., 2005. Anemia of inflammation: the hepcidin link. Current opinion in hematology, 12, 107–111.
  • Ruhe, J., et al., 2018. Intrinsic iron release is associated with lower mortality in patients with stable coronary artery disease-first report on the prospective relevance of intrinsic iron release. Biomolecules, 8 (3), 72.
  • Seferović, P.M., et al., 2019. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure, 21 (5), 553–576.
  • Ueda, N. and Takasawa, K., 2018. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients, 10 (9), 1173.
  • Vela, D., 2018. Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology. Laboratory investigation, 98 (3), 315–326.
  • Walter, P.B., et al., 2002. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proceedings of the national academy of sciences of the United States of America, 99 (4), 2264–2269.
  • Weinmann, K., et al., 2018. Add-on immunoadsorption shortly-after optimal medical treatment further significantly and persistently improves cardiac function and symptoms in recent-onset heart failure—a single center experience. Biomolecules, 8 (4), 133.
  • Zeller, T., et al., 2018. Prognostic value of iron-homeostasis regulating peptide hepcidin in coronary heart disease—evidence from the Large AtheroGene Study. Biomolecules, 8 (3), 43.
  • Zhang, H., et al., 2019. Role of iron metabolism in heart failure: from iron deficiency to iron overload. Biochimica et biophysica acta. Molecular basis of disease, 1865 (7), 1925–1937.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.